The main criteria of biomass selection for energy generation in Brazil

The principal aim of this paper is to examine the criteria assisting in the selection of biomass for energy generation in Brazil. To reach the aim, this paper adopts case study and survey research methods to collect information from four biomass energy case companies and solicits opinions from experts. The data gathered are analysed in line with a wide range of related data, including selection criteria for biomass and its importance, energy policies in Brazil, availability of biomass feedstock in Brazil and its characteristics, as well as status quo of biomass-based energy in Brazil. The findings of the paper demonstrate that there are ten main criteria in biomass selection for energy generation in Brazil. They comprise geographical conditions, availability of biomass feedstock, demand satisfaction, feedstock costs and oil prices, energy content of biomass feedstock, business and economic growth, CO2 emissions of biomass end-products, effects on soil, water and biodiversity, job creation and local community support, as well as conversion technologies. Furthermore, the research also found that these main criteria cannot be grouped on the basis of sustainability criteria, nor ranked by their importance as there is correlation between each criterion such as a cause and effect relationship, as well as some overlapping areas. Consequently, this means that when selecting biomass more comprehensive consideration is advisable.

Use of flucinolone acetonide for patients with diabetic macular oedema:patient selection criteria and early outcomes in real world setting

Introduction: Fluocinolone acetonide slow release implant (Iluvien®) was approved in December 2013 in UK for treatment of eyes which are pseudophakic with DMO that is unresponsive to other available therapies. This approval was based on evidence from FAME trials which were conducted at a time when ranibizumab was not available. There is a paucity of data on implementation of guidance on selecting patients for this treatment modality and also on the real world outcome of fluocinolone therapy especially in those patients that have been unresponsive to ranibizumab therapy. Method: Retrospective study of consecutive patients treated with fluocinolone between January and August 2014 at three sites were included to evaluate selection criteria used, baseline characteristics and clinical outcomes at 3-month time point. Results: Twenty two pseudophakic eyes of 22 consecutive patients were included. Majority of patients had prior therapy with multiple intravitreal anti-VEGF injections. Four eyes had controlled glaucoma. At baseline mean VA and CRT were 50.7 letters and 631 μm respectively. After 3 months, 18 patients had improved CRT of which 15 of them also had improved VA. No adverse effects were noted. One additional patient required IOP lowering medication. Despite being unresponsive to multiple prior therapies including laser and anti-VEGF injections, switching to fluocinolone achieved treatment benefit. Conclusion: The patient level selection criteria proposed by NICE guidance on fluocinolone appeared to be implemented. This data from this study provides new evidence on early outcomes following fluocinolone therapy in eyes with DMO which had not responded to laser and other intravitreal agents.